OncoMatch/Clinical Trials/NCT07332247
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
Is NCT07332247 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for nasopharangeal cancer.
This phase II randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation in locally advanced recurrent nasopharyngeal carcinoma. The study aims to determine whether sequential radiotherapy provides additional survival benefit beyond systemic immunochemotherapy.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy plus PD-1 inhibitor — recurrent
Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy
Cannot have received: radiotherapy, chemotherapy, immunotherapy, or biological therapy
No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent nasopharyngeal carcinoma
Cannot have received: PD-1/PD-L1 or CTLA-4 inhibitors
Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors
Cannot have received: anti-tumor therapy for recurrent nasopharyngeal carcinoma (including radiotherapy, chemotherapy, surgery, or immunotherapy)
Prior anti-tumor therapy for recurrent nasopharyngeal carcinoma, including radiotherapy, chemotherapy, surgery, or immunotherapy
Lab requirements
Blood counts
hemoglobin ≥ 90 g/l，anc ≥ 1.5 × 10⁹/l，platelet count ≥ 100 × 10⁹/l
Kidney function
creatinine ≤ 1.5 × uln, or creatinine clearance (crcl) / egfr ≥ 60 ml/min
Liver function
total bilirubin ≤ 1.5 × uln，ast and alt ≤ 2.5 × uln, or ≤ 5 × uln in the presence of liver metastases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify